FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209367162> ?p ?o ?g. }

• W3209367162 endingPage "1425" @default.
• W3209367162 startingPage "1417" @default.
• W3209367162 abstract "Colorectal cancer (CRC) is the second most common solid organ cancer. Traditional treatment is with surgery and chemotherapy. Immunotherapy has recently emerged as a neoadjuvant therapy that could change treatment strategy in both primary resectable and metastatic CRC.A literature review of PubMed with a focus on studies exploring upfront immunotherapy in operable CRC, either for primary resectable stage I-III cancers or for (potentially) operable liver metastasis.Immune checkpoint blockade by the programmed cell death 1 (PD-1) receptor inhibitors nivolumab and pembrolizumab and the cytotoxic T cell-associated protein 4 (CTLA-4) inhibitor ipilimumab has shown good results in both early-stage and advanced CRC. The effects of immune checkpoint inhibitors have so far been demonstrated in small phase I/II studies and predominantly in treatment-refractory stage IV disease with defect Mismatch repair (dMMR). However, recent data from phase I/II (NICHE-1) studies suggest an upfront role for immunotherapy in operable stage I-III disease. By blocking crucial immune checkpoints, cytotoxic T cells are activated and release cytotoxic signals that initiate cancer cell destruction. The very high complete response rate in dMMR operable CRC with neoadjuvant immunotherapy with nivolumab and ipilimumab, and even partial pathological response in some patients with proficient MMR (pMMR) CRC, calls for further attention to patient selection for neoadjuvant treatment, beyond MMR status alone.Early data on the effect of immunotherapy in CRC provide new strategic thinking of treatment options in CRC for both early-stage and advanced disease, with prospects for new trials.Immunotherapy has proven to be highly effective as first-line treatment of metastatic colorectal cancer (CRC). Further, immune checkpoint blockade by the programmed cell death 1 (PD-1) receptor inhibitors nivolumab and pembrolizumab and the cytotoxic T cell-associated protein 4 (CTLA-4) inhibitor ipilimumab has provided very good results in both early-stage and advanced CRC. The high response rate in dMMR in operable colon cancers by preoperative use of double nivolumab and ipilimumab therapy warrants further investigation into its impact on long-term overall survival. Hence, immunotherapy has emerged as a neoadjuvant approach, possibly changing treatment strategy for both primary resectable and metastatic CRC. Larger phase III trials are needed to evaluate overall effects on survival." @default.
• W3209367162 created "2021-11-08" @default.
• W3209367162 creator A5023509995 @default.
• W3209367162 creator A5056900546 @default.
• W3209367162 creator A5078476830 @default.
• W3209367162 date "2021-10-25" @default.
• W3209367162 modified "2023-10-14" @default.
• W3209367162 title "Neoadjuvant immunotherapy in primary and metastatic colorectal cancer" @default.
• W3209367162 cites W1535319703 @default.
• W3209367162 cites W1934094702 @default.
• W3209367162 cites W1940241680 @default.
• W3209367162 cites W2100471896 @default.
• W3209367162 cites W2117692326 @default.
• W3209367162 cites W2142300779 @default.
• W3209367162 cites W2159064822 @default.
• W3209367162 cites W2320280903 @default.
• W3209367162 cites W2569086487 @default.
• W3209367162 cites W2622499649 @default.
• W3209367162 cites W2739132742 @default.
• W3209367162 cites W2770647635 @default.
• W3209367162 cites W2784868445 @default.
• W3209367162 cites W2791557665 @default.
• W3209367162 cites W2802206159 @default.
• W3209367162 cites W2803558333 @default.
• W3209367162 cites W2804073610 @default.
• W3209367162 cites W2809907085 @default.
• W3209367162 cites W2891486030 @default.
• W3209367162 cites W2896640994 @default.
• W3209367162 cites W2897118246 @default.
• W3209367162 cites W2903814629 @default.
• W3209367162 cites W2904068706 @default.
• W3209367162 cites W2905043827 @default.
• W3209367162 cites W2907564726 @default.
• W3209367162 cites W2915944698 @default.
• W3209367162 cites W2916297485 @default.
• W3209367162 cites W2920863623 @default.
• W3209367162 cites W2923548794 @default.
• W3209367162 cites W2943196840 @default.
• W3209367162 cites W2943688939 @default.
• W3209367162 cites W2944675676 @default.
• W3209367162 cites W2947542980 @default.
• W3209367162 cites W2948127603 @default.
• W3209367162 cites W2949130394 @default.
• W3209367162 cites W2960393442 @default.
• W3209367162 cites W2960942904 @default.
• W3209367162 cites W2965186730 @default.
• W3209367162 cites W2965867002 @default.
• W3209367162 cites W2967681225 @default.
• W3209367162 cites W2982532966 @default.
• W3209367162 cites W2983284890 @default.
• W3209367162 cites W2988101401 @default.
• W3209367162 cites W3005693093 @default.
• W3209367162 cites W3007968106 @default.
• W3209367162 cites W3008389148 @default.
• W3209367162 cites W3009786850 @default.
• W3209367162 cites W3010538789 @default.
• W3209367162 cites W3015035400 @default.
• W3209367162 cites W3015633913 @default.
• W3209367162 cites W3016908025 @default.
• W3209367162 cites W3017379946 @default.
• W3209367162 cites W3021442601 @default.
• W3209367162 cites W3035309662 @default.
• W3209367162 cites W3037115677 @default.
• W3209367162 cites W3038274828 @default.
• W3209367162 cites W3047106569 @default.
• W3209367162 cites W3081777980 @default.
• W3209367162 cites W3083088281 @default.
• W3209367162 cites W3087050969 @default.
• W3209367162 cites W3091769666 @default.
• W3209367162 cites W3091949069 @default.
• W3209367162 cites W3092449327 @default.
• W3209367162 cites W3106891926 @default.
• W3209367162 cites W3107548995 @default.
• W3209367162 cites W3109638148 @default.
• W3209367162 cites W3110528877 @default.
• W3209367162 cites W3111488816 @default.
• W3209367162 cites W3120084637 @default.
• W3209367162 cites W3120427806 @default.
• W3209367162 cites W3121626582 @default.
• W3209367162 cites W3123349132 @default.
• W3209367162 cites W3125474097 @default.
• W3209367162 cites W3126208996 @default.
• W3209367162 cites W3126631762 @default.
• W3209367162 cites W3173553906 @default.
• W3209367162 cites W3174333127 @default.
• W3209367162 cites W3014460085 @default.
• W3209367162 cites W3162739858 @default.
• W3209367162 doi "https://doi.org/10.1093/bjs/znab342" @default.
• W3209367162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34694371" @default.
• W3209367162 hasPublicationYear "2021" @default.
• W3209367162 type Work @default.
• W3209367162 sameAs 3209367162 @default.
• W3209367162 citedByCount "50" @default.
• W3209367162 countsByYear W32093671622021 @default.
• W3209367162 countsByYear W32093671622022 @default.
• W3209367162 countsByYear W32093671622023 @default.
• W3209367162 crossrefType "journal-article" @default.
• W3209367162 hasAuthorship W3209367162A5023509995 @default.

• next